AstraZeneca PLC (AZN)
- Previous Close
75.03 - Open
75.00 - Bid 75.13 x 500
- Ask 75.18 x 500
- Day's Range
74.59 - 75.49 - 52 Week Range
60.47 - 75.81 - Volume
6,187,575 - Avg. Volume
6,389,106 - Market Cap (intraday)
233.06B - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
37.21 - EPS (TTM)
2.02 - Earnings Date --
- Forward Dividend & Yield 1.45 (1.93%)
- Ex-Dividend Date Feb 22, 2024
- 1y Target Est
81.72
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
www.astrazeneca.com89,900
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: AZN
Related Videos: AZN
Performance Overview: AZN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AZN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AZN
Valuation Measures
Market Cap
232.45B
Enterprise Value
258.98B
Trailing P/E
37.12
Forward P/E
17.86
PEG Ratio (5yr expected)
0.96
Price/Sales (ttm)
4.93
Price/Book (mrq)
6.22
Enterprise Value/Revenue
5.44
Enterprise Value/EBITDA
18.82
Financial Highlights
Profitability and Income Statement
Profit Margin
13.30%
Return on Assets (ttm)
7.04%
Return on Equity (ttm)
17.29%
Revenue (ttm)
47.61B
Net Income Avi to Common (ttm)
6.33B
Diluted EPS (ttm)
2.02
Balance Sheet and Cash Flow
Total Cash (mrq)
8.02B
Total Debt/Equity (mrq)
92.51%
Levered Free Cash Flow (ttm)
8.68B
Research Analysis: AZN
Company Insights: AZN
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: AZN
Analyst Report: AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.
RatingPrice TargetAnalyst Report: AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.
RatingPrice TargetAnalyst Report: AstraZeneca PLC
AstraZeneca is a British-Swedish company with its main headquarters in the U.K. and regional headquarters in Sweden and the U.S. It focuses on treatments for respiratory, autoimmune, and metabolic conditions, as well as on cardiology, neurology, and oncology drugs.
RatingPrice TargetMarket Update: CNP, HD, AZN, DLR, LIN
U.S. markets rallied on Thursday morning on stellar Nvidia results. On the housing front, existing home sales rose 3.1% to an annual rate of 4 million, this up from 3.8 million in December. The median home sales price was $379,100, 5.1% higher than a year ago, but down from $381,400 in December. As for economic trends, S&P Global's flash readings for February's PMI show expansion in both services and manufacturing. Services activity slowed to 51.3, down from 52.5 in January, but remained in expansion territory. Manufacturing PMI expanded more quickly in February with a reading of 51.7, up from 50.7 in January. The tech heavy Nasdaq rose 2.6%, the S&P 500 was up $1.8% and the Dow gained 0.8%